TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/25/2024
Back to search
Official data from USPTO
SHORLA PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
SHORLA PHARMA
ST13
US500000088861759Class
5, 42
Filing
88861759
Registration
6533302
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
23
Latest update
04/25/2024
Trademark type
Word
Nice classes
5, 42
Filing date
04/06/2020
Registration date
10/26/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/26/2021
Last transaction
04/25/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
99
Owner location
Clonmel, Co. Tipperary, IE
Examiner
MARTIN, CHRISTINE C
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Shorla Pharma Limited
Representatives
Sean P. McMahon SEAN P. MCMAHON, PLLC
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
pharmaceutical and medicinal preparations and substances for the treatment of metabolic diseases and disordersoncological diseases and disordersdermatological diseases and disordershormonal diseases and disordersviral diseases and disordersbacterial diseases and disordersinfectious diseases and disordersviral diseases and disorderas well as diseases and disorders of the alimentary tractcardiovascular systemmusculoskeletal systemcentral nervous systemperipheral nervous systemgenitourinary systemrespiratory system; pharmaceutical and medicinal preparations and substances for use in oncology; pharmaceutical preparations and substances for human use for the treatment of metabolic diseases and disordersoncological diseases and disordersdermatological diseases and disordershormonal diseases and disordersviral diseases and disordersbacterial diseases and disordersinfectious diseases and disordersviral diseases and disorderas well as diseases and disorders of the alimentary tractcardiovascular systemmusculoskeletal systemcentral nervous systemperipheral nervous systemgenitourinary systemrespiratory system; pharmaceutical preparations and substances for the prevention and treatment of cancer; pharmaceutical compounds for treating cancer; biological preparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of tumors; anti-cancer drugs and pharmaceutical preparations
Class 42
research and development services in the field of metabolic diseases and disordersoncological diseases and disordersdermatological diseases and disordershormonal diseases and disordersviral diseases and disordersbacterial diseases and disordersinfectious diseases and disordersviral diseases and disorderas well as diseases and disorders of the alimentary tractcardiovascular systemmusculoskeletal systemcentral nervous systemperipheral nervous systemgenitourinary systemrespiratory system; biological research; scientific research services; research and development services in the pharmaceutical and biotechnology fields; research services relating to the development and testing of pharmaceutical preparations and medicines; pharmaceutical drug development services; pharmaceutical product evaluation; testing and inspection of pharmaceutical preparations and medicines; conducting clinical trials for pharmaceutical products; product safety and quality testing in the pharmaceutical and biotechnology fields; provision of information and data relating to research and development in the pharmaceutical and biotechnology fields
Publications
History of USPTO decisions and trademark events.
23 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/25/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/25/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
10/26/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/10/2021
PUBO
PUBLISHED FOR OPPOSITION
08/10/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/21/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/01/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/09/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/09/2021
ALIE
ASSIGNED TO LIE
06/07/2021
NREV
NOTICE OF REVIVAL - E-MAILED
03/12/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/11/2021
PETG
PETITION TO REVIVE-GRANTED
03/11/2021
PROA
TEAS PETITION TO REVIVE RECEIVED
03/11/2021
MAB2
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
01/11/2021
ABN2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
01/11/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/29/2020
GNRT
NON-FINAL ACTION E-MAILED
06/29/2020
CNRT
NON-FINAL ACTION WRITTEN
06/29/2020
DOCK
ASSIGNED TO EXAMINER
06/24/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/14/2020
NWAP
NEW APPLICATION ENTERED
04/09/2020
Continuous trademark protection
Get notified about every new filing that threatens SHORLA PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.